drugset / Trial / NCT00363116
A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Phase 4
Completed
298 enrolled
University of Cincinnati
Roche Pharma AG · collabUniversity of Tennessee · collab
RandomizedSingle-groupOpen-labelPrevention
Summary
The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab in simultaneous kidney/pancreas transplant recipients.
Timeline
- Start
- 1999-04
- Primary completion
- 2004-12
- Completion
- 2004-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclizumab | Monoclonal antibody | 1 mg/kg | — |
| Comparator | Daclizumab | Monoclonal antibody | 2 mg/kg | — |